Patent US3999894A successfully refreshed from Google Patents.
Patent US3831582A successfully refreshed from Google Patents.
Patent JPH0346621A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4053628A Expired / Lapsed US ⏱️ 0.0 years remaining

Composition

Assignee: Fisons Ltd
•
Filing: 1976-04-15
•
Granted: 1977-10-11
•
Expires: 1996-04-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract There is described a composition comprising a substantially clear, sterile aqueous solution containing as active ingredient a therapeutically useful proportion of 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof, or of 5,5'-[[5,5'-(2-hydroxytrimethylene)dioxy]bis[4-oxo-4H-1-benzopyran-2-yl]]tetrazole, or a pharmaceutically acceptable (e.g. the di-sodium) salt thereof. The composition is indicated for the treatment of conditions of the eye and the nose.

Inventors

  • 👤 Neil Arthur Stevenson
  • 👤 George Wardell

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 11:14
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/41

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 47 words
A method of treatment of conditions of the eye or nose, in which conditions allergy or immune reactions play a contributory part, which method comprises administration of 1,3-bis(2-carboxychromon-5 -yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, topically or by sub-conjunctival injection to a patient having such a condition.
Claim 2
Independent Claim 47 words
A method of treatment of conditions of the eye or nose, in which conditions allergy or immune reactions play a contributory part, which method comprises administration of 1,3-bis(2-carboxychromon-5 -yloxy)propan-2-ol, or a pharmaceutically acceptable salt thereof, topically or by sub-conjunctival injection to a patient having such a condition.
Claim 3
Independent Claim 116 words
A method for the treatment of conditions of the eye or nose in which conditions allergy or immune reactions play a contributory part which comprises administering topically or by sub-conjunctival injection to a patient suffering from such condition a composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, wherein, in said composition, the said active ingredient is present in an amount of from 0.1 to 10% w/v, the said composition containes less than about 0.40 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the said composition being a substantially clear, sterile aqueous solution.
Claim 4
Independent Claim 116 words
A method for the treatment of conditions of the eye or nose in which conditions allergy or immune reactions play a contributory part which comprises administering topically or by sub-conjunctival injection to a patient suffering from such condition a composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, wherein, in said composition, the said active ingredient is present in an amount of from 0.1 to 10% w/v, the said composition containes less than about 0.40 ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the said composition being a substantially clear, sterile aqueous solution.
Claim 5
Independent Claim 131 words
A method for the treatment of conditions of the eye or nose in which conditions allergy or immune reactions play a contributory part which comprises administering topically or by sub-conjunctival injection to a patient suffering from such condition a composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, wherein, in said composition, the said active ingredient is present in an amount of from 0.1 to 10% w/v, the composition contains less than about 20ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the composition contains from about 0.05 to 0.1% w/v of a pharmaceutically acceptable chelating or sequestering agent, and the said composition is a substantially clear aqueous solution.
Claim 6
Independent Claim 131 words
A method for the treatment of conditions of the eye or nose in which conditions allergy or immune reactions play a contributory part which comprises administering topically or by sub-conjunctival injection to a patient suffering from such condition a composition which comprises a sterile aqueous solution containing 1,3-bis(2-carboxy-chromon-5-yloxy)-propan-2-ol or a pharmaceutically acceptable salt thereof as an active ingredient, wherein, in said composition, the said active ingredient is present in an amount of from 0.1 to 10% w/v, the composition contains less than about 20ppm of ions of metals in Groups IIa, Ib, IIb and IVb of the Periodic Table and of the transition metals, the composition contains from about 0.05 to 0.1% w/v of a pharmaceutically acceptable chelating or sequestering agent, and the said composition is a substantially clear aqueous solution.
Claim 7
Dependent Claim 60 words
A method according to claim 1 wherein the condition to be treated is a condition of the eye selected from the group of vernal catarrh, marginal corneal ulceration or infiltration, occular effects of hay fever, non-specific conjunctivitis, Herpes Simplex Keratitis and Conjunctivitis, Herpes Zoster Keratitis and Conjunctivitis, adenovirus infections, phlyctenular conjunctivitis, corneal homograft rejection, Trachoma, anterior uveitis and drug sensitivity.
Claim 8
Dependent Claim 35 words
A method according to claim 1 wherein the condition to be treated is a condition of the nose selected from the group of seasonal rhinitis, perennial rhinitis, nasal polyps and allergic manifestations of the nasopharynx.
Claim 9
Dependent Claim 37 words
A method according to claim 4 wherein the dosage to be administered is from 0.66 to 1.32 mg. of the 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol or pharmaceutically acceptable salt thereof to the affected eye from 2 to 4 times per day.

References Cited (Backward Citations)

US3671625A Cited
US3686412A Cited
US3777033A Cited
US3705945A Cited
US3720690A Cited
US3975536A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1980-10-10 1981-04-11 1981-10-11 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1984-10-10 1985-04-11 1985-10-11 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1988-10-10 1989-04-11 1989-10-11 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag